Corcept Therapeutics (CORT) Net Income towards Common Stockholders (2010 - 2026)

Corcept Therapeutics has reported Net Income towards Common Stockholders for 17 years, with the latest figure at $42.1 million in Q2 2026.

• Quarterly Net Income towards Common Stockholders rose 21.76% year-over-year to $42.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $54.2 million (down 58.93% YoY) and the FY2025 annual result came in at $98.2 million, down 29.74% from the prior year.
• Net Income towards Common Stockholders grew to $42.1 million in Q2 2026 per CORT's latest filing, from -$31.2 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $46.7 million in Q3 2024 and troughed at -$31.2 million in Q1 2026.
• A 5-year average of $25.3 million and a median of $27.5 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2023 and 2026: Net Income towards Common Stockholders soared 88.37% in 2023, then plunged 253.8% in 2026.
• Over 5 years, Net Income towards Common Stockholders stood at $16.5 million in 2022, then jumped by 88.37% to $31.1 million in 2023, then retreated by 2.42% to $30.4 million in 2024, then dropped by 21.34% to $23.9 million in 2025, then surged by 76.29% to $42.1 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $42.1 million, -$31.2 million, and $23.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.